Active surveillance in metastatic pancreatic neuroendocrine tumors: A 20-year single-institutional experience

Figure 1 Determination of the clinicopathological factors predicting time to progression during surveillance of metastatic pancreatic neuroendocrine tumors. A: Tumor burden of liver metastasis; B: Largest axis of the liver metastasis; C: T stage; D: M stage at diagnosis; E: Grade of liver metastasis; F: Grade of the primary tumor; G: Resection/transcatheter arterial chemoembolization of the liver metastasis; H: Resection of the primary tumor; I: Resection of the primary tumor in patients with stage IV disease. PanNET: Pancreatic neuroendocrine tumor; TACE: Transcatheter arterial chemoembolization; PD: Progressive disease.